Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Crystal Arthritis
When would you recommend uric acid-lowering therapy for a patient with asymptomatic hyperuricemia without comorbidities but with family history of gout?
Related Questions
Do you routinely recommend barbotage for calcific tendinopathy of the shoulder?
Do you avoid hyaluronic acid injections in patients with chondrocalcinosis on imaging?
Do you prefer allopurinol or febuxostat for patients with chronic kidney disease who are receiving treatment for asymptomatic hyperuricemia?
Can Milwaukee shoulder present with a large subacromial bursitis, or does it predominantly cause joint effusion/destruction?
Why are gout flares common in hospitalized patients undergoing diuresis but not commonly observed in cancer patients with hyperuricemia resulting from tumor lysis syndrome?
Do you delay pegloticase in a patient with an active gout flare?
Do you prefer using losartan in your patients with hypertension and gout due to its uricosuric effects?
How would you manage gout with hyperuricemia >10 mg/dl despite the maximum dose of allopurinol plus probenecid and a prior allergic reaction to pegloticase?
If a patient who has tolerated allopurinol for a prolonged period of time is subsequently found to be positive for the HLA-B*58:01 gene, how would you manage urate-lowering therapy thereafter?
How do you approach using DMARDs for patients with CPP arthritis who have frequent flares?
